Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers  - Data Presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - Health State Utility Index Data Estimate the Significant Health Burden of FXS, and Suggest the...

Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome DEVON, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...

Analog Legacy Protocol Enhancements GAITHERSBURG, Md., Oct. 22, 2019 (GLOBE NEWSWIRE) -- GL Communications Inc., a global leader in telecom test and measurement solutions, addressed the press regarding the T1 E1 Protocol Analyzer...

Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002 - Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - - Presentation Today at the 57th Annual...